drugset / Trial / NCT02932436

Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics

NCT02932436 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the EmDia trial is to compare the effects of empagliflozin with placebo in addition to standard diabetic treatment or dietetic treatment on cardiac diastolic function in patients with type 2 Diabetes mellitus.

Timeline

Start
2016-10-10
Primary completion
2020-06-15
Completion
2020-08-31

Outcome

Met primary endpoint

paper significant higher decrease in the primary endpoint E/e´ ratio by - 1.18 ([95% confidence interval (CI) - 1.72/- 0.65]; P < 0.0001) compared with placebo. PMID 36763159 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 10 mg Oral